Cargando…
Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer
BACKGROUND: Approximately 30 % of breast cancer patients receive chemotherapy, yet little is known about influences of current regimens on circulating lymphocyte levels and phenotypes. Similarly, clinico-pathological factors that modify these influences, and implications for future immune health rem...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727393/ https://www.ncbi.nlm.nih.gov/pubmed/26810608 http://dx.doi.org/10.1186/s13058-015-0669-x |
_version_ | 1782411957051064320 |
---|---|
author | Verma, Rashmi Foster, Ruth E. Horgan, Kieran Mounsey, Katherine Nixon, Helen Smalle, Natuley Hughes, Thomas A. Carter, Clive RD. |
author_facet | Verma, Rashmi Foster, Ruth E. Horgan, Kieran Mounsey, Katherine Nixon, Helen Smalle, Natuley Hughes, Thomas A. Carter, Clive RD. |
author_sort | Verma, Rashmi |
collection | PubMed |
description | BACKGROUND: Approximately 30 % of breast cancer patients receive chemotherapy, yet little is known about influences of current regimens on circulating lymphocyte levels and phenotypes. Similarly, clinico-pathological factors that modify these influences, and implications for future immune health remain mainly unexplored. METHODS: We used flow-cytometry to assess circulating lymphocyte levels and phenotypes in 88 primary breast cancer patients before chemotherapy and at time-points from 2 weeks to 9 months after chemotherapy completion. We examined circulating titres of antibodies against pneumococcal and tetanus antigens using ELISAs. RESULTS: Levels of B, T and NK cells were significantly reduced 2 weeks after chemotherapy (p < 0.001). B cells demonstrated particularly dramatic depletion, falling to 5.4 % of pre-chemotherapy levels. Levels of all cells recovered to some extent, although B and CD4(+) T cells remained significantly depleted even 9 months post-chemotherapy (p < 0.001). Phenotypes of repopulating B and CD4(+) T cells were significantly different from, and showed no sign of returning to pre-chemotherapy profiles. Repopulating B cells were highly depleted in memory cells, with proportions of memory cells falling from 38 % to 10 % (p < 0.001). Conversely, repopulating CD4(+) T cells were enriched in memory cells, which increased from 63 % to 75 % (p < 0.001). Differences in chemotherapy regimen and patient smoking were associated with significant differences in depletion extent or repopulation dynamics. Titres of anti-pneumococcal and anti-tetanus antibodies were both significantly reduced post-chemotherapy and did not recover during the study (p < 0.001). CONCLUSION: Breast cancer chemotherapy is associated with long-term changes in immune parameters that should be considered during clinical management. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13058-015-0669-x) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4727393 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-47273932016-01-27 Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer Verma, Rashmi Foster, Ruth E. Horgan, Kieran Mounsey, Katherine Nixon, Helen Smalle, Natuley Hughes, Thomas A. Carter, Clive RD. Breast Cancer Res Research Article BACKGROUND: Approximately 30 % of breast cancer patients receive chemotherapy, yet little is known about influences of current regimens on circulating lymphocyte levels and phenotypes. Similarly, clinico-pathological factors that modify these influences, and implications for future immune health remain mainly unexplored. METHODS: We used flow-cytometry to assess circulating lymphocyte levels and phenotypes in 88 primary breast cancer patients before chemotherapy and at time-points from 2 weeks to 9 months after chemotherapy completion. We examined circulating titres of antibodies against pneumococcal and tetanus antigens using ELISAs. RESULTS: Levels of B, T and NK cells were significantly reduced 2 weeks after chemotherapy (p < 0.001). B cells demonstrated particularly dramatic depletion, falling to 5.4 % of pre-chemotherapy levels. Levels of all cells recovered to some extent, although B and CD4(+) T cells remained significantly depleted even 9 months post-chemotherapy (p < 0.001). Phenotypes of repopulating B and CD4(+) T cells were significantly different from, and showed no sign of returning to pre-chemotherapy profiles. Repopulating B cells were highly depleted in memory cells, with proportions of memory cells falling from 38 % to 10 % (p < 0.001). Conversely, repopulating CD4(+) T cells were enriched in memory cells, which increased from 63 % to 75 % (p < 0.001). Differences in chemotherapy regimen and patient smoking were associated with significant differences in depletion extent or repopulation dynamics. Titres of anti-pneumococcal and anti-tetanus antibodies were both significantly reduced post-chemotherapy and did not recover during the study (p < 0.001). CONCLUSION: Breast cancer chemotherapy is associated with long-term changes in immune parameters that should be considered during clinical management. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13058-015-0669-x) contains supplementary material, which is available to authorized users. BioMed Central 2016-01-26 2016 /pmc/articles/PMC4727393/ /pubmed/26810608 http://dx.doi.org/10.1186/s13058-015-0669-x Text en © Verma et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Verma, Rashmi Foster, Ruth E. Horgan, Kieran Mounsey, Katherine Nixon, Helen Smalle, Natuley Hughes, Thomas A. Carter, Clive RD. Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer |
title | Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer |
title_full | Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer |
title_fullStr | Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer |
title_full_unstemmed | Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer |
title_short | Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer |
title_sort | lymphocyte depletion and repopulation after chemotherapy for primary breast cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727393/ https://www.ncbi.nlm.nih.gov/pubmed/26810608 http://dx.doi.org/10.1186/s13058-015-0669-x |
work_keys_str_mv | AT vermarashmi lymphocytedepletionandrepopulationafterchemotherapyforprimarybreastcancer AT fosterruthe lymphocytedepletionandrepopulationafterchemotherapyforprimarybreastcancer AT horgankieran lymphocytedepletionandrepopulationafterchemotherapyforprimarybreastcancer AT mounseykatherine lymphocytedepletionandrepopulationafterchemotherapyforprimarybreastcancer AT nixonhelen lymphocytedepletionandrepopulationafterchemotherapyforprimarybreastcancer AT smallenatuley lymphocytedepletionandrepopulationafterchemotherapyforprimarybreastcancer AT hughesthomasa lymphocytedepletionandrepopulationafterchemotherapyforprimarybreastcancer AT cartercliverd lymphocytedepletionandrepopulationafterchemotherapyforprimarybreastcancer |